In the News

Business Wire: Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies

April 8, 2016

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from several Phase 2 and Phase 3 studies evaluating its two investigational, pangenotypic, fixed-dose combination therapies for the treatment of chronic hepatitis C virus (HCV) infection, as well as new data highlighting the potential use of Harvoni® (ledipasvir/sofosbuvir) in adolescents aged 12 to 17. Data were presented […]


Science Daily: Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients

April 8, 2016

Scientists have uncovered a way to improve liver metabolism for those with non-alcoholic fatty liver disease by using an acute dose of an existing diabetes treatment. Read the full story at Science Daily


Healio: MAGELLAN-I: Novel regimen yields strong results in experienced patients with RAVs

April 8, 2016

Fred Poordad, M.D., of the Health Science Center, presents new findings on cirrhosis at the International Liver Congress in Barcelona.


MedPage Today: Combo Tx Offers ‘Salvage’ in Tough-to-Treat HCV

April 8, 2016

An investigational drug combination offers renewed hope of a cure for chronic hepatitis C (HCV) patients who have tried and failed therapy with the new direct-acting antiviral agents, a researcher said here. Read the full story at MedPage Today


Maine News Online: New hepatitis treatment

April 8, 2016

Medical researchers have claimed that an investigational combination of drugs can effectively treat chronic hepatitis C cases. Using the direct-acting antiviral agents used in the experimental treatment, the research team reported over 90 percent success rate for HCV patients. Read the full story at Maine News Online


Odessa American: Artificial sweeteners are not weight loss wonders

April 8, 2016

Studies show link between artificial sweeteners and obesity.